AAD 2026: Lumenis Launches triLIFT 2.0 for Combined Muscle and Skin Rejuvenation

Lumenis Be Ltd. announced the commercial launch of triLIFT 2.0, a next-generation platform designed to deliver combined muscle stimulation and skin rejuvenation for facial and body applications. The system integrates Dynamic Muscle Stimulation technology (DMSt) with FibroBoost, aiming to address both structural and dermal components of aging in a single treatment approach.

According to the company, triLIFT 2.0 is intended to provide muscle activation, skin tightening, and volumization. The DMSt component delivers high-intensity muscle contractions targeting deeper tissue layers, while FibroBoost uses radiofrequency-based energy delivered via ultrathin electrodes to stimulate collagen, elastin, and hyaluronic acid production.

Company-reported clinical data indicate that 94% of patients experienced improvement in facial muscle tone and lifting, while 90% showed improved facial skin tightness. In body applications, 100% of patients demonstrated measurable improvement at 1 month, and cellulite severity was reduced by 68% after four treatments. Treatment protocols typically include five facial sessions or six body sessions performed weekly.

The launch comes amid increased demand for noninvasive aesthetic treatments, including in patients experiencing skin laxity and volume changes associated with aging or rapid weight loss. Lumenis stated that the platform is designed to address both concerns simultaneously.

triLIFT 2.0 will be showcased at the 2026 American Academy of Dermatology Annual Meeting in Denver, Colorado, from March 27-31 at the Lumenis Booth #1123, and is now available for clinical use.